Among the 112 COVID-19-negative patients having received two doses of the BNT162b2 vaccine, the median anti-S1 antibody titre was 7.09 U/ml; this means that at least half of these patients had a titre below or barely above the supposedly neutralizing value and so were probably not sufficiently protected. This evidence concerns the gene PSMD1 and COVID-19.